Leerink lowered the firm’s price target on CVS Health (CVS) to $51 from $57 to account for the incremental uncertainty, while keeping a Market Perform rating on the shares. The firm is also updating its CVS estimates for Q4/FY25 due to incremental market details and updated views on the puts and takes currently impacting the overall enterprise. There’s an argument to be made that CVS is oversold and, given where the multiple sits vs. historical trading ranges, Leerink acknowledges that. However, it says that it is hard to ignore the cacophony of headline uncertainties being introduced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla
- Early notable gainers among liquid option names on December 18th
- PBMs took payments from manufacturers to allow free flow of opioids, NYT reports
- Trump Slams “Horrible Middlemen” and Sends CVS, UNH, & CI Stocks Tumbling
- PBM reform looks manageable for CVS Health, says UBS